Evidence signal01
The circadian hypothesis is testable
FDA reviewed melatonin-related and telomerase-related findings. Those signals explain scientific interest and can generate hypotheses.
FDA briefing pp. 29, 33–35Day 2 recordPCAC favorable
Peptide dossier / July 23–24, 2026Epitalon
A circadian hypothesis did not become direct insomnia evidence.
The official record contained circadian and melatonin-related findings, but no direct insomnia trial using the nominated SC product and no clinical safety record.
Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.
Editorial review
Analysis
FDA staff recommended against both forms; PCAC voted favorably on both form-level questions.
Decisive limitation02
Mechanism did not become an insomnia outcome
The record lacked direct behavioral or EEG sleep evidence, an SC insomnia trial, pharmacokinetic data and a clinical safety dataset.
FDA briefing pp. 29–40PeptideBase read
The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.
The case made in the room
Testimony
These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.
3published speaker moments
Only named speaker moments reconciled against a word-timestamped machine transcript of the official recording appear here. The method is two-pass transcript reconciliation: both passes read that same transcript, so this is not audio review and not independent primary-source confirmation. Where the two passes disagreed about who was speaking, the moment was withheld rather than published. Statements remain attributed arguments unless the underlying evidence was independently established from a named source outside the hearing record, and each moment carries its own disclosed limitations.
01Supports listing
Alex Tatem, MD
Board-certified urologist, private practice, Indianapolis
Verify credentialsAttributed testimony
The circadian-mechanism case
Tatem described a proposed circadian pathway connecting Epitalon with AANAT and melatonin restoration, and offered historical work as supporting context. A mechanistic account is not the same as a controlled insomnia result.
What is not established
- No credential is stated in this session. The credential shown is not taken from the hearing record at all — it comes from the linked independent practice profile.
- Automatic speech recognition renders the surname 'Tatum' throughout; the site displays the correct spelling, 'Tatem'. This is a transcription artefact, not an unresolved identity — the speaker is independently identified at the linked practice profile.
Epitalon session public comment · attributed argument, not an established factTranscript-reconciled — second review passedPlay the source03:54:43–03:58:30
02Supports listing
Jeffrey Egler, MD
Chief Medical Officer, Noom; American Academy of Peptide Medicine
Verify credentialsAttributed testimony
The undersold-nomination argument
Egler argued that FDA evaluated Epitalon against insomnia — where he agreed the human data is thin, resting on a single 20-day study of a melatonin metabolite by the sublingual rather than the nominated subcutaneous route — and that this undersold the aging-biomarker literature he considers the substance’s real clinical case.
“We respectfully ask the committee to recommend a listing of epitalon”
Epitalon session public comment · attributed argument, not an established factTranscript-reconciled — second review passedPlay the source03:38:39–03:40:58
03Opposes listing
Peter Lurie, MD, MPH
President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner
Verify credentialsAttributed testimony
The hearing-wide case against all seven
Lurie said CSPI opposed adding all seven substances, for three reasons: that listing would be inconsistent with FDA’s own compounding standards, that compounded products pose distinct consumer risks, and that listing would remove incentives to develop products through the standard drug-approval pathway.
What is not established
- Identity rests on a self-introduction plus the chair’s sequential numbering ("speaker number three"), not on the chair speaking his name.
BPC-157 session public comment, speaker #3 · explicitly applied to all seven substancesTranscript-reconciled — second review passedPlay the source00:57:02–00:59:43
A proposed melatonin and circadian mechanism supports an insomnia rationale for Epitalon.
Mechanistic and historicalWhat supports it
The testimony described cell-level and historical findings. A plausible mechanism does not show that the nominated subcutaneous product improves insomnia in patients.
FDA’s answer
FDA found no identified study in patients with insomnia via the proposed subcutaneous route and raised immunogenicity and continuous-exposure carcinogenicity concerns.
FDA Day 2 presentation · 04:26:12PeptideBase assessment
The circadian hypothesis is coherent enough to test. It is not a clinical insomnia result and does not answer route-specific or long-term safety questions.
Why the judgments diverged
Historical lineage and mechanism did not satisfy FDA’s use-specific test.
The favorable majority appears to have given weight to historical use, circadian biology and the prospect of regulated production. FDA centered its analysis on insomnia via the proposed subcutaneous route and found the clinical and safety record insufficient.
Editorial inference from the hearing record—not an attributed rationale for every voterClaim versus record
Claim checks
These are recurring propositions in the wider peptide discussion, not attributed speaker quotations.
Recurring claim
Melatonin findings establish that Epitalon treats insomnia.
Official record
FDA described melatonin-related findings but said the relevant monkey study did not assess sleep behavior or electroencephalographic sleep endpoints and that no nonclinical sleep-endpoint study was identified.
What it does not establish
FDA briefing pp. 29, 34A biomarker or mechanistic signal does not establish a clinically meaningful insomnia outcome.
Recurring claim
Telomerase activity establishes anti-aging benefit without a cancer concern.
Official record
FDA discussed telomerase and telomere-length findings and raised a potential carcinogenicity concern for chronic continuous exposure.
What it does not establish
FDA briefing pp. 33–35, 39–41The available intermittent-dose animal studies were too limited to resolve long-term risk; the concern is mechanistic and unresolved, not proof that Epitalon causes cancer.
Evidence architecture
Evidence
“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.
| Evidence question | Status | FDA-record summary | Locator |
|---|---|---|---|
| Human clinical evidence | absent | FDA-record summaryFDA identified no study in patients with insomnia using the proposed SC route. | LocatorBriefing pp. 29–32 |
| Nonclinical evidence | indirect | FDA-record summaryMelatonin and circadian signals were identified without behavioral or EEG sleep endpoints. | LocatorBriefing pp. 29, 34 |
| Exact-form match | unresolved | FDA-record summaryFDA reported that “it is often unclear whether the epitalon discussed in the sources considered for this section is the salt form or the free base,” and that the nominations were not consistent about which form was intended. | LocatorBriefing pp. 7–16 |
| Nominated-route match | absent | FDA-record summaryThe nominated SC route lacked direct insomnia effectiveness and human safety data. | LocatorBriefing pp. 29–32, 37–40 |
| Evaluated-use match | absent | FDA-record summaryFDA found no direct evidence supporting insomnia treatment with the nominated product. | LocatorBriefing pp. 29–32 |
| Product characterization | not well characterized | FDA-record summaryFDA concluded that “epitalon (free base) is considered not well-characterized from the physical and chemical characterization perspective,” citing inconsistent naming conventions and data on critical quality attributes that were lacking or inadequate; the same conclusion is stated for epitalon acetate. | LocatorBriefing pp. 8–21 |
| Human safety | absent | FDA-record summaryFDA said it identified no clinical safety data for Epitalon-related substances in humans. | LocatorBriefing pp. 35–40 |
| Historical compounding use | limited | FDA-record summaryFDA found the extent of historical compounding use unclear. | LocatorBriefing pp. 21–25 |
Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation
FDA findings
Five parts of the staff case.
01characterizationBoth epitalon free base and epitalon acetate were considered not well characterized.Day 2 pp. 81, 84
04:19:2602effectivenessFDA found a lack of evidence supporting effectiveness for insomnia, including no identified study in patients with insomnia via the proposed subcutaneous route.Day 2 p. 91
04:26:1203safetyFDA found no clinical safety data and raised concerns about potential immunogenicity and continuous-exposure carcinogenic risk.Day 2 pp. 92–98
04:28:0404historical useFDA found the extent of historical use in compounding unclear.Day 2 pp. 99–102
04:32:2405recommendationFDA proposed that neither epitalon free base nor epitalon acetate be included on the 503A Bulks List.Day 2 pp. 102–103
04:33:30
04:19:2602effectivenessFDA found a lack of evidence supporting effectiveness for insomnia, including no identified study in patients with insomnia via the proposed subcutaneous route.Day 2 p. 91
04:26:1203safetyFDA found no clinical safety data and raised concerns about potential immunogenicity and continuous-exposure carcinogenic risk.Day 2 pp. 92–98
04:28:0404historical useFDA found the extent of historical use in compounding unclear.Day 2 pp. 99–102
04:32:2405recommendationFDA proposed that neither epitalon free base nor epitalon acetate be included on the 503A Bulks List.Day 2 pp. 102–103
04:33:30
What changes the assessment
Sources
A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.
01
A controlled insomnia trial using the exact form and SC route
02
Clinical pharmacokinetic, immunogenicity and safety evidence
03
Long-term carcinogenicity and finished-product quality characterization
Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.
Continue the record
View all sevenRelated peptide dossiers
Day 2
Emideltide (DSIP)
Emideltide had older human studies, but the record was small, methodologically uneven and largely intravenous rather than the nominated subcutaneous route.
Open dossierDay 1MOTS-c
The scientific premise is mitochondrial and metabolic, but FDA said it found no clinical study or human-administration evidence and no adequate nonclinical toxicity package.
Open dossier